Category: Corona Virus

DENVER (KDVR) COVID-19 continues to rise in Colorado this week, including the incidence rates. Last week, the incidence rates were similar to the week before. This week, the incidence rates are rising again.

The states positivity rate is also rising, according to the Colorado Department of Public Health and Environment.

As of Monday, the states 7-day positivity rate is 7.45%, which is up from 6.84%. The highest positivity rate in the state over the past seven days is Delta County with 18.4% positivity.

From Oct. 4 to Oct. 11,42 counties saw an increase in COVID-19 positivity, 19 saw a decline in COVID-19 positivity, and three counties administered fewer than 10 tests in the past week.

According to theColorado Department of Public Health and Environment, the incidence rates have risen over the last seven days.

Heres a look atpositivity rates for every county over the last seven days:

Excerpt from:

What is happening with COVID-19 in Colorado? Its rising - FOX 31 Denver

It might not have been the immediate public inquiry sought by opposition parties and bereaved families, but the landmark joint report into the UKs handling of Covid proved less toothless than some feared.

Published almost exactly a year to the day since the MPs inquiry was first announced, the lessons learned to date report, prepared by two Commons committees after mammoth evidence sessions, is not short on lessons some of them expressed with notable bluntness.

The delay to impose a first lockdown last spring was one of the most important public health failures the United Kingdom has ever experienced; planning for a possible virus outbreak smacked of British exceptionalism; the lack of early testing capacity was an almost unimaginable setback.

The condemnation goes on, echoed through 151 pages, with just about the only element of the pandemic response spared a kicking being the vaccine rollout.

While the Commons health committee and science and technology committee are cross-party, taking in Labour and SNP members as well as Conservatives, they are led by Tory ex-ministers, Jeremy Hunt and Greg Clark.

Clark, the business secretary under Theresa May who was shunted to the backbenches by Boris Johnson, is unlikely to expect a return to ministerial life and has relatively little direct political investment in the issues scrutinised.

In contrast, Hunt was health secretary from 2012 to 2018 and was central to planning for such pandemics. He has clearly not relinquished the idea of coming back into government, or even competing again to be Tory leader, and would thus arguably have a vested interest in not overly upsetting either Boris Johnson or Conservative MPs more generally.

The Lib Dems had in particular expressed worry that Hunts involvement in pandemic preparations, including a report into a 2016 exercise based on the outbreak of a respiratory virus details of which only emerged in the Guardian last week made his hand in the report worrying.

While the final report, published on Tuesday, is highly critical of both ministers and scientists, opposition MPs involved said initial versions, notably its conclusions, were considerably less damning when first presented. It took many hours of robust debate to agree the final wording, they said.

Wrangling is standard on cross-party reports but the stakes here were high: the first official attempt to apportion some responsibility for what was arguably the greatest political crisis since the war, and one where the UK fared notably worse on several metrics than neighbouring countries.

The view from opposition parties is that the committees report showed what can be gained from such rapid inquiries but should be seen only as a start.

While Johnson has promised a full public inquiry into the pandemic, this will not begin until spring 2022 at the earliest. It was this delay that prompted Hunt and Clark to launch their own process, arguing it could avoid future errors.

It was, however, always a process with a limited scope and beset with political compromises. Thus, while many failings are outlined, they are generally institutional; there is nothing in the report likely to hasten the end of a ministerial career, or even to prompt an urgent question in parliament.

This isnt enough, one MP involved in the process said. We owe it to the families of those who died to get to the bottom of who got it wrong. And that needs a public inquiry.

Read more:

Damning Commons Covid report should be seen only as a start - The Guardian

A look at some of the top headlines trending online today around the world including the latest from Washington, coronavirus updates, Southwest cancellations and much more.

Navy nuclear engineer and wife arrested for trying to sell submarine secrets to foreign power (CBS News)

Southwest cancels more than a thousand flights, cites air-traffic control issues (Fox Business)

Treasury Secretary Yellen warns debt ceiling battle could spell catastrophe (ABC News)

Soaring Energy Prices Raise Concerns About U.S. Inflation, Economy (WSJ)

Florida cop says theres a lot of oddness in Brian Laundrie case (NY Post)

Small businesses navigate ever-changing COVID-19 reality (AP)

Merck asks FDA to authorize antiviral Covid pill for emergency use (CNBC)

Its too soon to declare victory against Covid-19 ahead of the holidays, but these festivities are safe to resume, experts say (CNN)

CBS News poll: Will parents get their younger kids vaccinated? (CBS)

As Bidens vaccinate-or-test mandate approaches, questions arise over enforcement (NBC)

Sydney reopens as Australia looks to live with COVID-19 (Reuters)

At least 15 shot, 1 dead, in hellish Minnesota bar shooting (NY Post)

No Time to Die Debuts at No. 1 at Domestic Box Office with $56 Million Opening Weekend (People)

Blue Origin New Shepard NS-18 launch with William Shatner delayed because of weather (Fox News)

Kim Kardashian Roasted Her Whole Family On SNL (BuzzFeed)

Georgia is No. 1 in USA TODAY AFCA Coaches Poll for first time since 2008 after Alabama loss (USA Today)

Original post:

Inflation, coronavirus, flight cancellations & more: Whats trending today - cleveland.com

Japan's new prime minister Fumio Kishida delivers his first policy speech at parliament in Tokyo, Japan, October 8, 2021. REUTERS/Kim Kyung-Hoon

TOKYO, Oct 12 (Reuters) - Japan's ruling Liberal Democratic Party (LDP) unveiled on Tuesday its manifesto for an Oct. 31 election with a focus on ending the coronavirus pandemic, promises to rebuild the middle class and defend against an increasingly assertive China.

The party's leader, Prime Minister Fumio Kishida, enjoys a reasonable level of public support a week into the job, polls show, boding well for his goal of maintaining a lower house majority for the LDP and its Komeito party coalition partner.

"We would like to show solid measures and appeal to the people, first, how to confront the coronavirus ... and to bring peace of mind and hope to the people," LDP policy chief Sanae Takaichi told a news conference.

Voters will want to see a government with plans for decisive action to bring an end to the pandemic and rebuild a weak economy. A recent Sankei newspaper poll showed that about 48% say they want the Kishida administration to work on coronavirus most, followed by economic recovery and employment.

The manifesto highlighted coronavirus measures including supplying oral antiviral medication this year, as well as Kishida's vision of realising a "new capitalism" that focuses on economic growth and redistribution of wealth.

The LDP said in its manifesto it would expand support for small and medium businesses hit by the pandemic and offer subsidies for enterprises if they move into new industries.

Fortunately for Kishida, the coronavirus situation has improved, with the smallest number of new cases on Monday since the middle of last year.

But Kishida is taking nothing for granted and told parliament earlier on Tuesday the government would plan for a worst-case coronavirus scenario by securing more health resources and preparing to start giving booster shots in December.

Asked about how the government would respond to excessive yen declines, Kishida said he would closely watch the impact of currency moves, noting that a weak yen increases costs for companies by pushing up import prices. read more

MORE ON DEFENCE

On security, the LDP said it would "reconsider" its response to an increase in China's military activity around the Taiwan strait and islets in the western Pacific controlled by Japan but also claimed by China.

The government would aim to raise its defence budget "with an eye to bringing it even above two percent" of gross domestic product (GDP), the party said.

Japan's defence spending has stayed around 1% of GDP in recent decades.

Kishida, a former foreign minister seen as a safe if lacklustre pair of hands, has a 49% approval rating, according to poll published by state-run broadcaster NHK late on Monday.

That is lower than the approval enjoyed by some predecessors at the beginning of their tenures but support for Kishida's government was higher than the most recent ratings for that of his predecessor, Yoshihide Suga.

Suga grew deeply unpopular as he struggled to contain a fifth wave of coronavirus infections and stepped down last month after only a year in office.

Kishida can take more cheer from the Sankey survey published on Monday that showed 63% of respondents supported his administration, with many voters saying there was no better person than him for the job of prime minister.

The poll showed a solid 45% rate of voter support for the LDP, with backing for opposition parties hovering around the single digits.

Reporting by Ju-min Park, Editing by Robert Birsel and Ed Osmond

Our Standards: The Thomson Reuters Trust Principles.

Here is the original post:

Japan's ruling party unveils manifesto with focus on coronavirus, defence - Reuters

Here are the latest local COVID-19statistics.

Dutchess County: 654 reported Monday, down 13 from the previous day. (Peak was 2,576 on Jan. 16.)

Ulster County: 288 reported Friday. (Peak was 2,622 on Jan. 30.) Ulster County did not provide updated information on the weekend or Monday.

Dutchess County: 2.8% (reported Monday).

Ulster County: 2.3% (reported Friday).

Dutchess County: 34,946 confirmed cases, 495 deaths. (No new deaths reported Monday).

Ulster County: 18,523 confirmed cases, 281 deaths.

Data as of Monday, according to New York statesonline vaccine tracker.

Ulster County: 65.6% of the population fully vaccinated, 72.3% with at least one dose of a two-dose regimen, 82.5% of the 18-and-older population with at least one dose.

Dutchess County: 60.4% fully vaccinated, 67.4% with at least one dose of a two-dose regimen, 77.7% of 18+ population with at least one dose.

Appointments: vaccinateulster.com, bit.ly/dut-vax, bit.ly/ny-vaxme.

For online local coverage related to the coronavirus, go todailyfreeman.com/tag/coronavirus.

Link:

Active cases of coronavirus decline in Dutchess County - The Daily Freeman

Last updated 16 April 2020

On 31 December 2019, WHO was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province of China. Chinese authorities identified the SARS-CoV-2 as the causative virus on 7 January 2020, and the disease was named coronavirus disease 2019 (COVID-19) by WHO on 11 February 2020. As part of WHOs response to the outbreak, a Research and Development (R&D) Blueprint has been activated to accelerate the development of diagnostics, vaccines and therapeutics for this novel coronavirus.

Under WHOs coordination, a group of experts with diverse backgrounds is working towards the development of vaccines against COVID-19.

The group makes a call to everyone to follow recommendations to prevent the transmission of the COVID-19 virus and protect the health of individuals. The group also thanks everyone for putting their trust in the scientific community.

We are scientists, physicians, funders and manufacturers who have come together as part of an international collaboration, coordinated by the World Health Organization (WHO), to help speed the availability of a vaccine against COVID-19.While a vaccine for general use takes time to develop, a vaccine may ultimately be instrumental in controlling this worldwide pandemic.In the interim, we applaud the implementation of community intervention measures that reduce spread of the virus and protect people, including vulnerable populations, and pledge to use the time gained by the widespread adoption of such measures to develop a vaccine as rapidly as possible. We will continue efforts to strengthen the unprecedented worldwide collaboration, cooperation and sharing of data already underway. We believe these efforts will help reduce inefficiencies and duplication of effort, and we will work tenaciously to increase the likelihood that one or more safe and effective vaccines will soon be made available to all.

Randy A. Albrecht, Icahn School of Medicine at Mount Sinai, USA

Mohamad Assoum, Mercy Global Health

Luigi Aurisicchio, on behalf of Takis Biotech, Italy

Dan Barouch, Center for Virology and Vaccine Research, USA

Trevor Brasel, The University of Texas Medical Branch (UTMB), USA

Jennifer L Bath, ImmunoPrecise Antibodies, Canada

Sina Bavari, Edge BioInnovation Consulting and Management, USA

Maria Elena Bottazzi, Baylor College of Medicine, Houston, USA

Gerhard Beck,Austrian Medicines and Medical Devices, Austria

Tom Brady, Flow Pharma Inc, USA

Kate Broderick, Inovio, USA

Will Brown, Altimmune Inc, USA

Dirk Busch, Maura Dandri, Dirk Heinz and Hans-Georg Kraeusslich, on behalf of the German Center for Infection Research - DZIF, Germany

Scot Bryson, Orbital Farm, Canada

Ricardo Carrin, Texas Biomedical Research Institute, USA

Miles Carroll, Public Health England, UK

Keith Chappell, University of Queensland, Australia

Daniel S. Chertow, National Institutes of Health, U.S. Department of Health and Human Services, USA

Sandra Cordo, Universidad de Buenos Aires, Argentina

Wian de Jongh, on behalf of the Prevent n-CoV consortium (AdaptVac, ExpreS2ion, Copenhagen University, Leiden University Medical Centre, Wageningen University and Tubingen University)

Natalie Dean, University of Florida, USA

Rafael Delgado, Hospital Universitario 12 de Octubre, Spain

Dimiter Dimitrov

David A. Dodd, GeoVax, Inc., USA

Paul Duprex, Center for Vaccine Research, University of Pittsburgh, USA

Luis Enjuanes; Centro Nacional Biotecnologa, Spain

Jeremy Farrar, Josie Golding, Charlie Weller, on behalf of Wellcome Trust, UK

Mark Feinberg, Swati Gupta and Ripley Ballou, on behalf of IAVI, USA

Antonella Folgori, on behalf of ReiThera, Italy

Thomas Friedrich, University of Wisconsin, School of Veterinary Medicine, USA

Simon Funnel, Public Health England, UK

Luc Gagnon, Nexelis, Canada

Adolfo Garcia-Sastre, Icahn School of Medicine at Mount Sinai, USA

Vipin Garg, Altimmune Inc., USA

Volker Gerdts, on behalf of VIDO-Intervac, University of Saskatchewan, Canada

Nora Gerhards, Wageningen Bioveterinary Research, The Netherlands

Christiane Gerke, Head of Vaccine Programs/Head of Vaccine Innovation Development, Institut Pasteur, France

Carlo Giaquinto, Department of Women and Child Health, University of Padova, Italy

Prakash Ghimire, Tribhuvan University, Nepal

Nikolaj Gilbert, Program for Appropriate Technology in Health (PATH), USA

Sarah Gilbert, University of Oxford, UK

Marion F. Gruber, Food and Drug Administration, U.S. Department of Health and Human Services, USA

Farshad Guirakhoo, GeoVax Inc, USA

Bart L Haagmans, Erasmus Medical Center, The Netherlands

M. Elizabeth Halloran, Center for Inference and Dynamics of Infectious Diseases, Fred Hutchinson Cancer Research Center, and University of Washington, USA

Scott Harris, Altimmune Inc, USA

Hideki Hasegawa, National Institute of Infectious Diseases, Japan

Richard Hatchett, on behalf of the Coalition for Epidemic Preparedness Innovations (CEPI), Norway

James Hayward, Applied DNA Sciences, USA

Sheri Ann Hild

Peter Hotez, Baylor College of Medicine, USA

Youngmee Jee, Seoul National University, College of Medicine, Republic of Korea

Charu Kaushic, Institute of Infection and Immunity, Canadian Institutes of Health Research (CIHR), Government of Canada

Alyson A. Kelvin, Dalhousie University, Canada

Larry D. Kerr, Office of Global Affairs, U.S. Department of Health and Human Services, USA

Bernard Kerscher, PEI, Germany

Jae-Ouk Kim, International Vaccine Institute, Republic of Korea

Seungtaek Kim, Institut Pasteur Korea, Republic of Korea

Jason Kindrachuk, University of Manitoba, Canada

Otfried Kistner, Senior Consultant and Independent Vaccine Expert, Austria

Gary Kobinger, Universit Laval, Canada

Marion Koopmans, Viroscience Department, Erasmus Medical Centre, The Netherlands

Jeroen Kortekaas, Wageningen Bioveterinary Research, the Netherlands

Philip R. Krause, Food and Drug Administration, U.S. Department of Health and Human Services, USA

Greg Kulnis, Nexelis, Canada

Paul Henri Lambert, Centre of Vaccinology, University of Geneva, Switzerland

Nathalie Landry, Medicago Inc., Canada

Roger Le Grand, Inserm-CEA-Universit Paris Saclay, France

Robin Levis, Food and Drug Administration, U.S. Department of Health and Human Services, USA

Mark G Lewis, Bioqual Inc, USA

Joshua Liang, Clover Biopharmaceuticals, China

Jinzhong Lin, on behalf of Fudan University, China

Ira Longini, University of Florida, USA

Shabir Madhi, University of the Witwatersrand, Johannesburg, South Africa

Jessica E. Manning, National Institutes of Health, U.S. Department of Health and Human Services, USA

Peter Marks, Director, on behalf of Food and Drug Administration/Center for Biologics Evaluation and Research

Hilary D. Marston, National Institutes of Health, U.S. Department of Health and Human Services, USA

Federico Martinn-Torres, Hospital Clnico Universitario de Santiago de Compostela, Spain

Sebastian Maurer-Stroh, on behalf of the GISAID Initiative

John W. Mellors, University of Pittsburgh School of Medicine, USA

Ali Mirazimi, Department of Laboratory medicin, Karolinska institutet, Sweden

Kayvon Modjarrad, Walter Reed Army Institute of Research, USA

Stefan O. Mueller, CureVac, Germany

Vincent J. Munster, National Institutes of Health, U.S. Department of Health and Human Services, USA

Csar Muoz-Fontela, Bernhard-Nocht-Institute for Tropical Medicine, Germany

Aysegul Nalca, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), USA

Jos Manuel Ochoa, Altimmune Inc., USA

Dave O'Connor, University of Wisconsin-Madison, USA

Lidia Oostvogels, CureVac, Germany

Nisreen M. A. Okba, Erasmus Medical Center, The Netherlands

L. Jean Patterson, National Institutes of Health, U.S. Department of Health and Human Services, USA

Joe Payne, on behalf of Arcturus Therapeutics

Jonathan Pearce, on behalf of the UK Research and Innovation (UKRI) and the Medical Research Council (MRC), UK

Stanley Perlman, University of Iowa, USA

See the original post here:

Public statement for collaboration on COVID-19 vaccine ...

Dieser Text stellt eine Basisinformation dar. Eine Gewhr fr die Richtigkeit und Vollstndigkeit der Angaben kann nicht bernommen werden. Aufgrund unterschiedlicher Aktualisierungsrhythmen knnen Statistiken einen aktuelleren Datenstand aufweisen.

Read the original here:

Statista - das Statistik-Portal: Statistiken, Marktdaten ...

Sign up for The Brief, our daily newsletter that keeps readers up to speed on the most essential Texas news.

Texas Republican gubernatorial candidate Allen West, who is not vaccinated against COVID-19, tweeted on Saturday that he may be admitted to the hospital after a chest X-ray showed he has pneumonia caused by the virus.

Theres a concern about my oxygen saturation levels, which are at 89 and they should be at 95, West tweeted, adding in a follow-up tweet, My chest X-rays do show COVID pneumonia, not serious. I am probably going to be admitted to the hospital.

Earlier in the day, Wests campaign tweeted that his wife, who is vaccinated against COVID-19, had tested positive for the virus on Friday. In that tweet thread, the campaign said he was experiencing a low grade fever and light body aches and that he was canceling in-person events until he was in the clear. In the same thread, the campaign also said that West was taking hydroxychloroquine and ivermectin.

The U.S. Food and Drug Administration has said both drugs can cause serious health problems for people who take the drugs to attempt to treat COVID-19.

Hydroxychloroquine is an anti-malaria drug that the FDA has said has no benefit for decreasing the likelihood of death or speeding recovery. Ivermectin is a drug used to treat parasites in humans and animals; the FDA has said that Currently available data do not show ivermectin is effective against COVID-19.

West tweeted that he and his wife both completed monoclonal antibody treatment and were "in the observation period."

Wests campaign said in the tweets that he believes getting vaccinated against COVID-19 should be a personal choice.

On Oct. 7, West tweeted a photo from an event he attended for Mission Generation, an evangelical organization, in Seabrook, outside of Houston, describing it as a packed house. The two photos West shared depicted attendees without masks.

West represented Florida in Congress from 2011 to 2013 before moving to Texas in 2014 to become the CEO of the National Center for Policy Analysis, a Dallas think tank that shuttered three years later.

Last year, West was elected to be the state party chair, a position he resigned in June to challenge Gov. Greg Abbott in the Republican primary next year.

Visit link:

Allen West, GOP candidate for governor, says he has pneumonia caused by COVID-19 - The Texas Tribune

A Canadian study has found a link between the new variants of SARS-CoV-2, particularly the Delta variant, and an increased risk of severe disease and death.

The retrospective study, by the University of Toronto and appearing in the Canadian Medical Association Journal (CMAJ), looked at 212,326 cases in Ontario from February 7 to June 27, 2021. The study authors compared the risks of hospitalization, ICU admission, and death from the VOCs with those risks from non-VOC SARS-CoV-2 strains.

The researchers screened the cases for Alpha, Beta, Gamma, and Delta VOCs. Non-VOC infections made up 22.4% of the cases. More than three-quarters of the cases were Alpha, Beta, or Gamma, while 2.8% were probably Delta.

Alpha, Beta, and Gamma variants have a mutation that increases transmission, while Delta has a mutation that increases its ability to replicate.

Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.

The authors note that before May 2021, there was no routine screening for the Delta variant, so it is likely that the numbers underestimate the prevalence of this variant.

The present study found that all VOCs increased peoples risk of hospitalization, ICU admission, and death due to COVID-19.

However, the highest risks were from the Delta variant. In the Delta cases, there was a 108% increase in the risk of hospitalization, a 235% increased risk of ICU admission, and a 133% higher risk of death, compared with the original variant.

These effects were present even when the researchers adjusted the data for factors such as age, sex, vaccination status, and comorbidities.

Prof. William Schaffner, infectious diseases specialist at the Vanderbilt University Medical Center in Nashville, TN, commented:

This important study from Canada reinforces the serious impact the Delta variant is having. It is well recognized that Delta is more contagious than other virus variants. This new study convincingly reinforces the finding that it also causes more severe disease.

The Delta variant is now the dominant variant in the European Union, the United Kingdom, and the United States.

The findings of the present study corroborate those of the studies in England, Scotland, and Singapore that have also shown increased risks from the Delta variant.

Speaking to Medical News Today, Dr. Christopher Coleman, assistant professor of infection immunology at the University of Nottingham in the U.K., highlighted the international relevance of the study.

He said, Although this [Canadian] study has some limitations, as acknowledged by the authors, this is exactly the kind of study that helps build a picture by showing that similar observations can be observed in a lot of different circumstances.

It is not something unique about the U.K. that means the Delta variant is associated with more dangerous infections only here, he added.

Some good news from this study is that vaccination, both partial and complete, reduced the risk of severe disease and death from all the VOCs. During the course of the study, as vaccination numbers increased, hospitalizations, ICU admissions, and deaths decreased.

These results from Canada now add to those from studies from England, Scotland, and Singapore, all showing that Delta infection causes more severe disease. Fortunately, our currently available vaccines continue to provide good protection against severe Delta infections.

Prof. William Schaffner

The authors highlight that these VOCs have led to a pandemic that is larger and more deadly than it would otherwise have been.

Dr. Kirsten Patrick, interim editor-in-chief of the CMAJ, observed that most COVID-19 patients who required critical care were unvaccinated, but said, The virus has become smarter and more dangerous, which means that we need to be smarter too.

She stressed that we must use all the tools at our disposal to prevent future lockdowns. As well as boosting vaccination rates, governments must continue with measures such as extending vaccine mandates and passports, ensuring global vaccine delivery, and continuing to identify, track, and control outbreaks.

For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.

See original here:

Delta has 235% higher risk of ICU admission than original coronavirus - Medical News Today

'); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); if (val.poly != "" && val.polyimg != "") { $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).append('"+val.ihtml+""); $("#expandable-weather-block .weather-index-alerts").show(); $("#expandable-weather-block .modal-body h2").css({"font-family":"'Fira Sans', sans-serif", "font-weight":"500", "padding-bottom":"10px"}); $("#expandable-weather-block .modal-body p").css({"font-size":"14px", "line-height":"24px"}); $("#expandable-weather-block .modal-body span.wxalertnum").css({"float":"left", "width":"40px", "height":"40px", "color":"#ffffff", "line-height":"40px", "background-color":"#888888", "border-radius":"40px", "text-align":"center", "margin-right":"12px"}); $("#expandable-weather-block .modal-body b").css("font-size", "18px"); $("#expandable-weather-block .modal-body li").css({"font-size":"14px", "line-height":"18px", "margin-bottom":"10px"}); $("#expandable-weather-block .modal-body ul").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body pre").css({"margin-bottom":"24px"}); $("#expandable-weather-block .modal-body img").css({"width":"100%", "margin-bottom":"20px", "borderWidth":"1px", "border-style":"solid", "border-color":"#aaaaaa"}); $("#expandable-weather-block .modal-body #mrd-alert"+ alertCount).css({"borderWidth":"0", "border-bottom-width":"1px", "border-style":"dashed", "border-color":"#aaaaaa", "padding-bottom":"10px", "margin-bottom":"40px"}); }); } function parseAlertJSON(json) { console.log(json); alertCount = 0; if (Object.keys(json.alerts).length > 0) { $("#mrd-wx-alerts .modal-body ").empty(); } $.each(json.alerts, function(key, val) { alertCount++; $("#mrd-wx-alerts .alert_count").text(alertCount); $("#mrd-wx-alerts .modal-body ").append(''); $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(""+val.title+""); if (val.poly != "" && val.polyimg != "") { $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } else if (val.fips != "" && val.fipsimg != "") { // $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(''); } $("#mrd-wx-alerts .modal-body #mrd-alert"+ alertCount).append(val.dhtml+"

Instruction

75F

Continue reading here:

Ivey extends limited COVID-19 health emergency to Oct. 31 - FOX10 News